Recurrent ALK Positive Large B-Cell Lymphoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Recurrent ALK Positive Large B-Cell Lymphoma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT06834373

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C…

This phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen receptor (CAR) T-cell therapy in patients…

United States41 participantsStarted 2025-04-02

Treatment: Biospecimen Collection, Bone Marrow Aspiration

All recent trials (5 shown)

Active — Not RecruitingPhase 2

NCT05507541

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

This phase II trial tests the safety, side effects, and best dose of TTI-621 (closed to enrollment) or TTI-622 in combination with pembrolizumab in treating pat…

United States10 participantsStarted 2023-04-19

Treatment: Biospecimen Collection, Computed Tomography

Active — Not RecruitingPhase 2

NCT03038672

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

This phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have come back (recur…

United States54 participantsStarted 2018-12-21

Treatment: Nivolumab, Varlilumab

Recurrent ALK Positive Large B-Cell Lymphoma

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C…

All recent trials (5 shown)

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C…

All recent trials (5 shown)

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL